8-K: DURECT Acquired by Bausch Health for $1.75/Share Plus CVR

DURECT Corporation has completed its acquisition by Bausch Health Americas, Inc. for $1.75 per share in cash plus a contingent value right.

Summary

• DURECT Corporation was acquired by Bausch Health Americas, Inc. through its subsidiary, BHC Lyon Merger Sub, Inc., with the acquisition completed on September 11, 2025.
• DURECT is now an indirect wholly owned subsidiary of Bausch Health Americas, Inc.
• The tender offer, which commenced on August 12, 2025, and expired on September 10, 2025, resulted in 19,984,767 Company Shares being validly tendered, representing approximately 62% of outstanding shares.
• Shareholders received $1.75 in cash per share and one non-tradeable contingent value right (CVR) for each Company Share.
• Each CVR represents the right to a pro rata portion of two potential additional net sales milestone payments of up to $350 million in aggregate, contingent on achievement before December 31, 2045, or the 10-year anniversary of the first commercial sale in the U.S.
• The acquisition was funded by Parent using cash and was not subject to any financing condition.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive for DURECT shareholders who received a cash premium and potential future upside via CVRs. For the company, it marks a successful exit and integration into a larger entity, though it ceases independent public operations.

Positives

• Shareholders received a cash payment of $1.75 per share, representing a premium for their shares.
• Shareholders received a contingent value right (CVR) offering potential future payments up to $350 million based on net sales milestones, providing an opportunity for additional returns.
• In-the-money stock options were accelerated and treated identically to other Company Shares in the offer, providing liquidity for option holders.

Negatives

• DURECT Corporation ceased to be an independent publicly traded company, ending its separate corporate existence.
• Company Shares were delisted from Nasdaq and will be deregistered, terminating public reporting obligations.
• Existing stockholders (other than those exercising appraisal rights) ceased to have any rights as stockholders of DURECT, other than the right to receive the Offer Consideration.
• Out-of-the-money stock options were canceled without exercise, resulting in no value for those holders.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and dependent on the achievement of future net sales milestones, which may not occur.
• CVRs are non-tradeable, limiting liquidity for holders and preventing them from selling their rights in the market.

Future Outlook

DURECT Corporation will operate as an indirect wholly owned subsidiary of Bausch Health Americas, Inc., with its common stock delisted and deregistered from public trading. The future financial performance of DURECT will be integrated into Bausch Health's reporting. The potential for CVR payments depends on future net sales milestones.

Industry Context

This acquisition reflects ongoing consolidation within the pharmaceutical and biotechnology sectors, where larger companies acquire smaller, often specialized, firms to expand their product pipelines, intellectual property, or market share. Bausch Health's acquisition of DURECT, a biopharmaceutical company, aligns with a strategy to potentially enhance its portfolio, particularly if DURECT's pipeline assets achieve commercial success, as indicated by the CVR structure.

Comparison to Industry Standards

• The acquisition price of $1.75 per share plus CVRs is a common structure in biotech M&A, allowing acquirers to limit upfront costs while providing target shareholders with upside potential tied to product performance.
• The 62% tender rate, satisfying the minimum condition, is typical for successful tender offers leading to a short-form merger.
• The delisting and deregistration process following an acquisition is standard procedure for a company becoming a wholly-owned subsidiary.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received cash consideration and CVRs, but lost direct equity ownership and liquidity for DURECT shares.
• Employees: Board of Directors changed; impact on other employees not specified but typically involves integration into the acquiring company's structure.
• Customers/Suppliers: No direct impact mentioned, but DURECT's operations will now be under Bausch Health's umbrella, potentially affecting future business relationships.

Next Steps

• Nasdaq is expected to file Form 25 with the SEC on September 11, 2025, to effect the delisting of DURECT's common stock.
• DURECT intends to file Form 15 with the SEC to terminate registration and suspend reporting obligations under the Exchange Act.
• Payment for all validly tendered and accepted Company Shares will be promptly made.
• Potential future payments to CVR holders if net sales milestones are achieved.

Key Dates

Keywords

DURECT Corporation, Bausch Health, acquisition, merger, tender offer, CVR, contingent value right, delisting, biopharmaceutical, corporate governance, DRRX